Niche health site reports traffic jump

Share this article:
Niche health site reports traffic jump
Niche health site reports traffic jump
Multimedia diabetes network dLife said total visits to its website crossed the one-million mark for the month of November.

The milestone represents a 35% increase versus Nov. 2008 in visits and page views for the diabetes-focused site, the network said, citing Google Analytics stats.

Commenting on the growth, Greg Zegras, dLife chief operating officer, told MM&M, “It's a culmination of improvements we've been making to the site over the last 12 months as well as a peak in awareness around [the American Diabetes Association's] American Diabetes Month.”

Zegras said the network has been investing in online tools, including recipes and a food look-up that shows detailed nutritional analyses—information important to patients and caregivers. In addition, an online community was launched last January enabling users to create profiles, share comments and post photos.

The mix has proved attractive to advertisers in the diabetes vertical. The site's current pharmaceutical brand lineup includes Pfizer's Lyrica, which is approved for treating diabetic nerve pain, as well as Novo Nordisk's insulin line, Lantus (Sanofi-Aventis), Glucagon and Humalog KwikPen (Eli Lilly), Byetta (Amylin/Lilly), Avandia (GlaxoSmithKline) and Actos (Takeda).

DLife, whose media outlets also include the dLifeTV program, said the following companies have recently aired ads against the TV show: Merck for Januvia, Sanofi-Aventis for Lantus and Roche for its AccuCheck glucose meter. The dLifeTV program appears Sunday evenings on CNBC.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...